Literature DB >> 31728439

Viral pneumonia and pulmonary alveolar proteinosis: the cause and the effect, case report.

Saeed Mishal Albogami1, Abdelfattah A Touman2.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of amorphous lipoproteinaceous material in the distal air spaces due to defective surfactant clearance by alveolar macrophages. This leads to impaired gas exchange and arterial hypoxemia of varying degrees. Although autoimmune type of PAP is thought to be idiopathic, this focused report highlights the possible relationship between viral pneumonia and autoimmune PAP (APAP) in terms of causation, superinfection and effect of treatments. We report a newly diagnosed case of APAP with a possible viral causation "trigger" for the confirmed serum anti-granulocyte macrophage-colony stimulating factor (GM-CSF) antibody. To the best of our knowledge, this is the first report that describe and discuss this issue. The patient is a 38-year-old, ex-smoker woman who had had a progressively worsening dyspnea and a persistent, productive cough for more than 4 months. It was thought to be a community acquired pneumonia (CAP) case and was treated with multiple antibiotics which yielded no improvement in her condition. Physical examination revealed mild hypoxemia and minimal bilateral fine crepitations despite marked alveolar filling on chest X-ray (CXR). She underwent a bronchoscopic procedure that revealed PAP. The case also describes an acute flare up of the condition during the course of the disease caused by a confirmed H1N1 influenza infection. APAP should be considered in the differential diagnosis of recurrent pneumonia not responding to treatment. In this case report we suggest the possible role of viral causation "trigger" or cross-reactivity of GM-CSF antibodies that lead to APAP. We also describe the provided management, the response to the antiviral therapy and the diagnostic and management challenges that was encountered during the follow up. 2019 AME Case Reports. All rights reserved.

Entities:  

Keywords:  Case report; granulocyte macrophage-colony stimulating factor (GM-CSF); influenza; periodic acid Schiff (PAS); pulmonary alveolar proteinosis (PAP); whole lung lavage (WLL)

Year:  2019        PMID: 31728439      PMCID: PMC6851454          DOI: 10.21037/acr.2019.09.04

Source DB:  PubMed          Journal:  AME Case Rep        ISSN: 2523-1995


  19 in total

1.  Pulmonary alveolar proteinosis associated with Epstein-Barr virus infection.

Authors:  C Edwards; R Primhak; M C Cohen
Journal:  Eur Respir J       Date:  2010-11       Impact factor: 16.671

Review 2.  Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management.

Authors:  Isham Huizar; Mani S Kavuru
Journal:  Curr Opin Pulm Med       Date:  2009-09       Impact factor: 3.155

3.  Occupational inhalational exposure and serum GM-CSF autoantibody in pulmonary alveolar proteinosis.

Authors:  Yong-Long Xiao; Kai-Feng Xu; Yan Li; Yan Li; Hui Li; Bin Shi; Ke-Feng Zhou; Zheng-Yang Zhou; Hou-Rong Cai
Journal:  Occup Environ Med       Date:  2015-05-20       Impact factor: 4.402

Review 4.  Occupational and environmental scleroderma. Systematic review and meta-analysis.

Authors:  Manuel Rubio-Rivas; Rafael Moreno; Xavier Corbella
Journal:  Clin Rheumatol       Date:  2017-01-14       Impact factor: 2.980

5.  Pulmonary alveolar proteinosis in four siblings.

Authors:  K Teja; P H Cooper; J E Squires; P T Schnatterly
Journal:  N Engl J Med       Date:  1981-12-03       Impact factor: 91.245

6.  Resolution of secondary pulmonary alveolar proteinosis following treatment of rhinocerebral aspergillosis.

Authors:  Kun-Pei Lin; Wang-Huei Sheng; Cheng-Ping Wang; Yih-Leong Chang; Shang-Chwen Chang
Journal:  Int J Infect Dis       Date:  2010-02-01       Impact factor: 3.623

7.  [A case of pulmonary alveolar proteinosis which initially deteriorated rapidly with exacerbation of pulmonary nocardiosis, responded promptly to treatment of the pulmonary nocardiosis].

Authors:  Shozaburo Yamaguchi; Noboru Takayanagi; Daido Tokunaga; Yutaka Sugita; Yoshinori Kawabata
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2010-08

8.  GM-CSF in the lung protects against lethal influenza infection.

Authors:  Fang-Fang Huang; Peter F Barnes; Yan Feng; Ruben Donis; Zissis C Chroneos; Steven Idell; Timothy Allen; Daniel R Perez; Jeffrey A Whitsett; Kyri Dunussi-Joannopoulos; Homayoun Shams
Journal:  Am J Respir Crit Care Med       Date:  2011-04-07       Impact factor: 21.405

Review 9.  Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review.

Authors:  U B Prakash; S S Barham; H A Carpenter; D E Dines; H M Marsh
Journal:  Mayo Clin Proc       Date:  1987-06       Impact factor: 7.616

Review 10.  Pulmonary alveolar proteinosis: progress in the first 44 years.

Authors:  John F Seymour; Jeffrey J Presneill
Journal:  Am J Respir Crit Care Med       Date:  2002-07-15       Impact factor: 21.405

View more
  2 in total

Review 1.  The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review.

Authors:  Ali Ataya; Vijaya Knight; Brenna C Carey; Elinor Lee; Elizabeth J Tarling; Tisha Wang
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

2.  GM-CSF antibodies in artificial stone associated silicoproteinosis: A case report and literature review.

Authors:  Shana N S Khan; Robert G Stirling; Catriona A Mclean; Prudence A Russell; Ryan F Hoy
Journal:  Respirol Case Rep       Date:  2022-08-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.